French pharma major Sanofi (Euronext: SAN) has reported final quarter 2020 sales of 9.4 billion euros ($11.3 billion), bringing the year’s total to 36 billion euros, up 3.3%.
Quarterly revenues relied heavily on a strong performance from the interleukin (IL)-4 and IL-13 blocker Dupixent (dupilumab), with sales soaring to 982 million euros, an increase of 54%.
Nonetheless, the overall result fell short of many analysts’ expectations, with the FT consensus forecast having come in at 9.6 billion euros for the quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze